Gan & Lee Pharmaceuticals Co. Ltd. has prepared and tested proteolysis targeting chimera (PROTAC) compounds comprising an E3 ubiquitin ligase binding moiety covalently linked to an estrogen receptor α(ER-α; ESR1) targeting moiety via a linker reported to be useful for the treatment of cancer.
Gan & Lee Pharmaceuticals Co. Ltd. has discovered proteolysis targeting chimera (PROTAC) compounds comprising a cereblon (CRBN) binding agent coupled to interleukin-1 receptor-associated kinase 4 (IRAK-4) targeting moiety through a linker acting as IRAK-4 degradation inducers reported to be useful for the treatment of cancer, inflammatory and immunological disorders.
Gan & Lee Pharmaceuticals Co. Ltd. has described protein cereblon (CRBN) inhibitors and proteolysis targeting chimera (PROTAC) compounds reported to be useful for the treatment of cancer.
SMARCA4 and SMARCA2 are essential subunits of the SWI/SNF complex, functioning as ATP-dependent chromatin remodelers that regulate gene expression and maintain cellular homeostasis. Recent research has shown that selectively targeting SMARCA2 is an effective cancer treatment strategy, with several compounds already in early clinical testing.
Gan & Lee Pharmaceuticals Co. Ltd. has synthesized antibody-drug conjugates comprising a monoclonal antibody covalently linked to exatecan derivatives through a linker reported to be useful for the treatment of cancer.
Gan & Lee Pharmaceuticals Co. Ltd. has described new S-adenosylmethionine synthase isoform type-2 (Mat2A) inhibitors reported to be useful for the treatment of cancer.
Gan & Lee Pharmaceuticals’ long-acting GLP-1 receptor agonist (GLP-1 RA), GZR-18, achieved as much as 17.29% weight loss in a phase IIb trial in obese and overweight Chinese patients. Developed independently by Shanghai-based Gan & Lee, GZR-18 is a once-weekly or potentially biweekly GLP-1 RA being developed to treat adults with type 2 diabetes and for weight management for obese or overweight patients.
HONG KONG – Venture capital investment into most sectors in China has generally plunged throughout the COVID-19 pandemic but biotechnology has been a noticeable exception. China’s biotech industry has continued to attract investors, not only because of its importance in dealing with the pandemic but also as a result of increased maturity and a growing list of government incentives.
HONG KONG – Venture capital investment into most sectors in China has generally plunged throughout the COVID-19 pandemic but biotechnology has been a noticeable exception.
